The ZymoBIOMICS Fecal Reference with TruMatrix™ Technology is a microbial reference material composed of stool from healthy donors for quality control, process validation, assay development, and proficiency testing. The fecal reference was homogenized in one large batch to produce consistency in every vial, eliminating typical lot-to-lot variability. With over 2 million preps available, this reference is intended to be used as a control for workflow performance, as well as comparing workflow consistency across replicates, studies, and laboratories. To facilitate methods comparison, a platform is in development to enable users to compare characterization data against applied methodology.

The Quick-16S Plus NGS Library Prep Kit (V3-V4, UDI) is the fastest and simplest NGS library prep targeting the V3-V4 region of the 16S rRNA gene for high-throughput sequencing. The automation-friendly protocol utilizes a single qPCR/PCR for combined targeted amplification and barcode addition using specially designed primers. After pooling by equal volume, a single clean-up of the final library is performed, rather than massive AMPure^® bead-based clean-ups. Additional library quantification analysis such as TapeStation^® analysis or gel electrophoresis are not necessary. With these features, the workflow dramatically reduces the hands-on time of library preparation to only 30 minutes.

The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.

EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.

MORE INFORMATION FROM ONE REACTION

• PCR kit detects and distinguishes Herpes Simplex Virus 1 and Herpes Simplex Virus 2 in a single reaction tube

EXCELLENT QUALITY

• The highest possible diagnostic sensitivity (100.00%) and diagnostic specificity (97.62%)

SIMPLE LABORATORY WORKFLOW

• Easily combinable with other GeneProof PCR kits in one workflow

As a product of Panagene (Korea), the PANAMAX ™ 48 automatic extraction device works on the principle of using lysis and binding of samples by magnetic particles. Along with 3 samples kit ready-for-use for the process of extracting DNA/RNA/ccfDNA, this is the solution automatically 100%, just adding the sample to the correct specified wells, the […]

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

PANA RealTyper^TM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition